(Q34135558)

English

Averting inflammation by targeting the cytokine environment

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Averting inflammation by targeting the cytokine environment (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

object named as

Manfred Kopf

1

0 references

Martin F. Bachmann

2

object named as

Martin F Bachmann

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Benjamin J Marsland

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

703-718

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Virus interference. I. The interferon

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Virus interference. II. Some properties of interferon

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

What makes a good anti-inflammatory drug target?

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Inflammation and cancer: how hot is the link?

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Granulomatous infections due to tumor necrosis factor blockade: correction

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Reactivation of latent granulomatous infections by infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

An essential role for ectodomain shedding in mammalian development

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-6: from basic science to medicine--40 years in immunology

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 6 plays a key role in the development of antigen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 6 is required for the development of collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-6 is required for the development of Th1 cell-mediated murine colitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Evidence for continuous stimulation of interleukin-6 production in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anti-interleukin-6 antibodies in normal human serum

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anti‐Interleukin‐6 Autoantibodies in Plasma are Associated with an Increased Frequency of Infections and Increased Mortality of Patients with Alcoholic Cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Use of canakinumab in the cryopyrin-associated periodic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A pilot study of IL-1 inhibition by anakinra in acute gout

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Molecular identification of a danger signal that alerts the immune system to dying cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Gout-associated uric acid crystals activate the NALP3 inflammasome

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Anakinra for rheumatoid arthritis: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Involvement of Tumor Necrosis Factor-α in the Development of T Cell–Dependent Aortitis in Interleukin-1 Receptor Antagonist–Deficient Mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Colony-stimulating factors in inflammation and autoimmunity.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

T(H)-17 cells in the circle of immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Th17 cell differentiation: the long and winding road

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

The biological functions of T helper 17 cell effector cytokines in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Cutting Edge: IL-21 Is Not Essential for Th17 Differentiation or Experimental Autoimmune Encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Functional diversity of helper T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A rush to judgment on Th17

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Genetic dissection of immunity to mycobacteria: the human model

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-17 family cytokines and the expanding diversity of effector T cell lineages

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-17 and Th17 Cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Cytokine-mediated regulation of antimicrobial proteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Inflammatory bowel disease and mutations affecting the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 and TGF-beta are required for differentiation of human T(H)17 cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A fundamental role for interleukin-21 in the generation of T follicular helper cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

T follicular helper (TFH) cells in normal and dysregulated immune responses

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

IL-25 regulates Th17 function in autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A role for TSLP in the development of inflammation in an asthma model

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Asthma: mechanisms of disease persistence and progression

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Immunodrugs: therapeutic VLP-based vaccines for chronic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin

1 reference

https://api.crossref.org/works/10.1038%2FNRD2805

31 March 2020

Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lethal tuberculosis in interleukin-6-deficient mutant mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20811382

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NRD2805

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34135558&oldid=2196294185"